ADMA
Another day, another legal notice
ADMA Biologics investors got a fresh reminder that the securities-fraud saga is still very much alive. Rosen Law Firm says buyers of ADMA shares between August 9, 2024 and March 25, 2026 have until August 10 to step up as lead plaintiff in the class action.
Why investors should care
This isn’t the kind of headline that helps the vibe. A lead-plaintiff deadline keeps the case in the conversation, and that can mean more legal overhang for a stock that already has to deal with the usual biotech math: growth story on one side, lawsuit noise on the other.
The annoying part
What makes these notices so repetitive is also what makes them sticky:
- the alleged issues cover a long class period
- the deadline gives investors a calendar reminder they can’t ignore
- even if the case doesn’t change the company’s business overnight, it can hang around like a bad group chat notification
Big picture
For ADMA holders, this is less about a surprise and more about the lawsuit staying front and center. The stock doesn’t get to move on until the market feels it has a better handle on the legal risk.